Faden H, Duffy L
Department of Pediatrics, State University of New York, Buffalo.
Am J Dis Child. 1992 Nov;146(11):1320-3. doi: 10.1001/archpedi.1992.02160230078023.
To determine the effect of an asymptomatic nonpolioviral infection on the immune response to poliovirus vaccines.
Open comparative trial.
Well-child clinic at The Children's Hospital of Buffalo, NY.
Twenty-seven healthy infants infected with nonpolioviruses and 27 healthy controls matched for age and vaccine group.
Trivalent oral attenuated poliovirus vaccine or enhanced potency inactivated vaccine administered at ages 4 and 12 months.
MEASUREMENTS/MAIN RESULTS: Neutralizing antibody to poliovirus serotypes 1, 2, and 3 were determined in the serum and nasopharyngeal secretion samples obtained at ages 4, 5, 12, and 13 months. The IgA antibody titers for polioviruses 1, 2, and 3 were measured in nasopharyngeal secretion samples during the same periods. Antibody responses to poliovirus vaccines were similar in coinfected subjects and healthy controls at ages 5 and 13 months, except for serum neutralizing antibody that was significantly elevated in the controls compared with coinfected subjects (geometric mean [+/- SD] antibody titers, 12.7 +/- 1.6 vs 11.5 +/- 1.7). Concurrent viral infections affected the immune response in recipients of the oral poliovirus vaccine and the enhanced-potency inactivated poliovirus vaccine similarly. The immune response to polioviruses 1 and 3 were more adversely affected by coinfection than was the immune response to poliovirus 2.
Concurrent asymptomatic viral infections minimally impaired the immune response to poliovirus vaccines. The adverse effects of coinfection were considered clinically insignificant.
确定无症状非脊髓灰质炎病毒感染对脊髓灰质炎疫苗免疫反应的影响。
开放比较试验。
纽约州布法罗市儿童医院的健康儿童诊所。
27名感染非脊髓灰质炎病毒的健康婴儿以及27名年龄和疫苗组相匹配的健康对照。
在4个月和12个月龄时给予三价口服减毒脊髓灰质炎病毒疫苗或高效灭活疫苗。
测量指标/主要结果:在4、5、12和13个月龄时采集的血清和鼻咽分泌物样本中测定针对脊髓灰质炎病毒1、2和3型的中和抗体。在同一时期,测定鼻咽分泌物样本中脊髓灰质炎病毒1、2和3型的IgA抗体滴度。在5个月和13个月龄时,合并感染的受试者和健康对照对脊髓灰质炎疫苗的抗体反应相似,但对照组血清中和抗体与合并感染的受试者相比显著升高(几何平均[±标准差]抗体滴度,12.7±1.6对11.5±1.7)。同时发生的病毒感染对口服脊髓灰质炎病毒疫苗和高效灭活脊髓灰质炎病毒疫苗接种者的免疫反应影响相似。与对脊髓灰质炎病毒2型的免疫反应相比,合并感染对脊髓灰质炎病毒1型和3型的免疫反应影响更大。
同时发生的无症状病毒感染对脊髓灰质炎疫苗免疫反应的损害极小。合并感染的不良影响在临床上被认为无足轻重。